| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
An anthelmintic used in most schistosome and many cestode infestations. [PubChem] |
| Indication |
For the treatment of infections due to all species of schistosoma. |
| Pharmacology |
Praziquantel is an anthelmintic used in most schistosome and many cestode infestations. Praziquantel effects the permeability of the cell membrane resulting in the contraction of schistosomes. The drug further causes vacuolization and disintegration of the schistosome tegument. The effect is more marked on adult worms compared to young worms. An increased calcium influx may play an important role. Secondary effects are inhibition of glucose uptake, lowering of glycogen levels and stimulation of lactate release. The action of praziquantel is limited very specifically to trematodes and cestodes; nematodes (including filariae) are not affected. |
| Biotransformation |
renal |
| Absorption |
Rapidly absorbed (80%) |
| Half Life |
0.8-1.5 hours (in serum) |
| Protein Binding |
80 to 85% |
| References |
| • |
Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008 Dec;21(6):659-67.
[Pubmed]
|
| • |
McManus DP, Loukas A: Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008 Jan;21(1):225-42.
[Pubmed]
|
|
| External Links |
|